Design of Bimodal Ligands of Neurotensin Receptor 1 for Positron Emission Tomography Imaging and Fluorescence-Guided Surgery of Pancreatic Cancer.
Emma RenardPierre-Alix DancerChristophe PortalFranck DenatAurélie PrignonVictor GoncalvesPublished in: Journal of medicinal chemistry (2020)
Neurotensin receptor 1 (NTSR1) is overexpressed in most human pancreatic ductal adenocarcinomas. It makes it an attractive target for the development of pancreatic cancer imaging agents. In this study, we sought to develop a bimodal positron emission tomography (PET)/fluorescent imaging agent capable of specifically targeting these receptors. Starting from the structure of a known NTSR1 agonist, a series of tracers were synthesized, radiometalated with gallium-68, and evaluated in vitro and in vivo, in mice bearing an AsPC-1 xenograft. PET imaging allowed us to identify the compound [68Ga]Ga-NODAGA-Lys(Cy5**)-AEEAc-[Me-Arg8,Tle12]-NT(7-13) as the one with the most promising biodistribution profile, characterized by high tumor uptake (2.56 ± 0.97%ID/g, 1 h post-injection) and rapid elimination from nontargeted organs, through urinary excretion. Fluorescence imaging gave similar results. On this basis, fluorescence-guided resection of tumor masses was successfully carried out on a preclinical model.
Keyphrases
- positron emission tomography
- pet imaging
- pet ct
- computed tomography
- fluorescence imaging
- high resolution
- photodynamic therapy
- endothelial cells
- minimally invasive
- magnetic resonance imaging
- type diabetes
- quantum dots
- mesenchymal stem cells
- magnetic resonance
- adipose tissue
- acute coronary syndrome
- mass spectrometry
- percutaneous coronary intervention
- binding protein
- bone marrow
- squamous cell
- cell therapy